Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis

P. de Graeff; A.P.G. Crijns; S. de Jong; M. Boezen; W.J. Post; E.G.E. de Vries; A.G.J. van der Zee; G.H. de Bock

doi:10.1038/sj.bjc.6605112

Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis

P. de Graeff, A.P.G. Crijns, S. de Jong, M. Boezen, W.J. Post, E.G.E. de Vries, A.G.J. van der Zee, G.H. de Bock

Research output: Contribution to journal › Review article › peer-review

97 Citations (Scopus)

293 Downloads (Pure)

Abstract

BACKGROUND: P53, EGFR and HER-2/neu are the most frequently studied molecular biological parameters in epithelial ovarian cancer, but their prognostic impact is still unequivocal. We performed a meta-analysis to more precisely estimate their prognostic significance.

METHODS: Published studies that investigated the association between p53, EGFR and HER-2/neu status and survival were identified. Meta-analysis was performed using a DerSimonian-Laird model. Publication bias was investigated using funnel plots and sources of heterogeneity were identified using meta-regression analysis.

RESULTS: A total of 62 studies were included for p53, 15 for EGFR and 20 for HER-2/neu. P53, EGFR and HER-2/neu status had a modest effect on overall survival (pooled HR 1.47, 95% CI 1.33-1.61 for p53; HR 1.65, 95% CI 1.25-2.19 for EGFR and HR 1.67, 95% CI 1.34-2.08 for HER-2/neu). Meta-regression analysis for p53 showed that FIGO stage distribution influenced study outcome. For EGFR and HER-2/neu, considerable publication bias was present.

CONCLUSIONS: Although p53, EGFR and HER-2/neu status modestly influences survival, these markers are, by themselves, unlikely to be useful as prognostic markers in clinical practice. Our study highlights the need for well-defined, prospective clinical trials and more complete reporting of results of prognostic factor studies. British Journal of Cancer ( 2009) 101, 149-159. doi: 10.1038/sj.bjc.6605112 www.bjcancer.com Published online 9 June 2009 (C) 2009 Cancer Research UK

Original language	English
Pages (from-to)	149-159
Number of pages	11
Journal	British Jounal of Cancer
Volume	101
Issue number	1
DOIs	https://doi.org/10.1038/sj.bjc.6605112
Publication status	Published - 30-Jun-2009

Keywords

p53
EGFR
HER-2/neu
ovarian cancer
meta-analysis
EPIDERMAL-GROWTH-FACTOR
GYNECOLOGIC-ONCOLOGY-GROUP
FACTOR RECEPTOR EXPRESSION
PLATINUM-BASED CHEMOTHERAPY
TUMOR-SUPPRESSOR GENE
PROTEIN EXPRESSION
MULTIVARIATE-ANALYSIS
SIGNALING PATHWAY
POOR-PROGNOSIS
EARLY-STAGE

Access to Document

10.1038/sj.bjc.6605112Licence: CC BY-NC-SA

Modest effect of p53, EGFR and HER-2/neu on prognosisFinal publisher's version, 271 KBLicence: CC BY-NC-SA

Handle.net

Persistent link

Cite this

@article{c68c48cc5d92468eab349a6748673989,

title = "Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis",

abstract = "BACKGROUND: P53, EGFR and HER-2/neu are the most frequently studied molecular biological parameters in epithelial ovarian cancer, but their prognostic impact is still unequivocal. We performed a meta-analysis to more precisely estimate their prognostic significance.METHODS: Published studies that investigated the association between p53, EGFR and HER-2/neu status and survival were identified. Meta-analysis was performed using a DerSimonian-Laird model. Publication bias was investigated using funnel plots and sources of heterogeneity were identified using meta-regression analysis.RESULTS: A total of 62 studies were included for p53, 15 for EGFR and 20 for HER-2/neu. P53, EGFR and HER-2/neu status had a modest effect on overall survival (pooled HR 1.47, 95% CI 1.33-1.61 for p53; HR 1.65, 95% CI 1.25-2.19 for EGFR and HR 1.67, 95% CI 1.34-2.08 for HER-2/neu). Meta-regression analysis for p53 showed that FIGO stage distribution influenced study outcome. For EGFR and HER-2/neu, considerable publication bias was present.CONCLUSIONS: Although p53, EGFR and HER-2/neu status modestly influences survival, these markers are, by themselves, unlikely to be useful as prognostic markers in clinical practice. Our study highlights the need for well-defined, prospective clinical trials and more complete reporting of results of prognostic factor studies. British Journal of Cancer ( 2009) 101, 149-159. doi: 10.1038/sj.bjc.6605112 www.bjcancer.com Published online 9 June 2009 (C) 2009 Cancer Research UK",

keywords = "p53, EGFR, HER-2/neu, ovarian cancer, meta-analysis, EPIDERMAL-GROWTH-FACTOR, GYNECOLOGIC-ONCOLOGY-GROUP, FACTOR RECEPTOR EXPRESSION, PLATINUM-BASED CHEMOTHERAPY, TUMOR-SUPPRESSOR GENE, PROTEIN EXPRESSION, MULTIVARIATE-ANALYSIS, SIGNALING PATHWAY, POOR-PROGNOSIS, EARLY-STAGE",

author = "{de Graeff}, P. and A.P.G. Crijns and {de Jong}, S. and M. Boezen and W.J. Post and {de Vries}, E.G.E. and {van der Zee}, A.G.J. and {de Bock}, G.H.",

year = "2009",

month = jun,

day = "30",

doi = "10.1038/sj.bjc.6605112",

language = "English",

volume = "101",

pages = "149--159",

journal = "British Jounal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer

T2 - a meta-analysis

AU - de Graeff, P.

AU - Crijns, A.P.G.

AU - de Jong, S.

AU - Boezen, M.

AU - Post, W.J.

AU - de Vries, E.G.E.

AU - van der Zee, A.G.J.

AU - de Bock, G.H.

PY - 2009/6/30

Y1 - 2009/6/30

N2 - BACKGROUND: P53, EGFR and HER-2/neu are the most frequently studied molecular biological parameters in epithelial ovarian cancer, but their prognostic impact is still unequivocal. We performed a meta-analysis to more precisely estimate their prognostic significance.METHODS: Published studies that investigated the association between p53, EGFR and HER-2/neu status and survival were identified. Meta-analysis was performed using a DerSimonian-Laird model. Publication bias was investigated using funnel plots and sources of heterogeneity were identified using meta-regression analysis.RESULTS: A total of 62 studies were included for p53, 15 for EGFR and 20 for HER-2/neu. P53, EGFR and HER-2/neu status had a modest effect on overall survival (pooled HR 1.47, 95% CI 1.33-1.61 for p53; HR 1.65, 95% CI 1.25-2.19 for EGFR and HR 1.67, 95% CI 1.34-2.08 for HER-2/neu). Meta-regression analysis for p53 showed that FIGO stage distribution influenced study outcome. For EGFR and HER-2/neu, considerable publication bias was present.CONCLUSIONS: Although p53, EGFR and HER-2/neu status modestly influences survival, these markers are, by themselves, unlikely to be useful as prognostic markers in clinical practice. Our study highlights the need for well-defined, prospective clinical trials and more complete reporting of results of prognostic factor studies. British Journal of Cancer ( 2009) 101, 149-159. doi: 10.1038/sj.bjc.6605112 www.bjcancer.com Published online 9 June 2009 (C) 2009 Cancer Research UK

AB - BACKGROUND: P53, EGFR and HER-2/neu are the most frequently studied molecular biological parameters in epithelial ovarian cancer, but their prognostic impact is still unequivocal. We performed a meta-analysis to more precisely estimate their prognostic significance.METHODS: Published studies that investigated the association between p53, EGFR and HER-2/neu status and survival were identified. Meta-analysis was performed using a DerSimonian-Laird model. Publication bias was investigated using funnel plots and sources of heterogeneity were identified using meta-regression analysis.RESULTS: A total of 62 studies were included for p53, 15 for EGFR and 20 for HER-2/neu. P53, EGFR and HER-2/neu status had a modest effect on overall survival (pooled HR 1.47, 95% CI 1.33-1.61 for p53; HR 1.65, 95% CI 1.25-2.19 for EGFR and HR 1.67, 95% CI 1.34-2.08 for HER-2/neu). Meta-regression analysis for p53 showed that FIGO stage distribution influenced study outcome. For EGFR and HER-2/neu, considerable publication bias was present.CONCLUSIONS: Although p53, EGFR and HER-2/neu status modestly influences survival, these markers are, by themselves, unlikely to be useful as prognostic markers in clinical practice. Our study highlights the need for well-defined, prospective clinical trials and more complete reporting of results of prognostic factor studies. British Journal of Cancer ( 2009) 101, 149-159. doi: 10.1038/sj.bjc.6605112 www.bjcancer.com Published online 9 June 2009 (C) 2009 Cancer Research UK

KW - p53

KW - EGFR

KW - HER-2/neu

KW - ovarian cancer

KW - meta-analysis

KW - EPIDERMAL-GROWTH-FACTOR

KW - GYNECOLOGIC-ONCOLOGY-GROUP

KW - FACTOR RECEPTOR EXPRESSION

KW - PLATINUM-BASED CHEMOTHERAPY

KW - TUMOR-SUPPRESSOR GENE

KW - PROTEIN EXPRESSION

KW - MULTIVARIATE-ANALYSIS

KW - SIGNALING PATHWAY

KW - POOR-PROGNOSIS

KW - EARLY-STAGE

U2 - 10.1038/sj.bjc.6605112

DO - 10.1038/sj.bjc.6605112

M3 - Review article

C2 - 19513073

VL - 101

SP - 149

EP - 159

JO - British Jounal of Cancer

JF - British Jounal of Cancer

SN - 0007-0920

IS - 1

ER -